Approximately 3 billion people have been exposed to hepatitis B virus (HBV) 
antigen found on the surface of normal and malignant B lymphomas and is used alone or in combination with cytotoxic therapy. In 2001, Dervite et al (7) first reported a possible relationship between HBV reactivation and rituximab use in a patient with anti-HBs. After that report, some cases of reactivation of HBV in patients following treatment with rituximab that may prove fatal were reported (8) (9) (10) (1) . Thus, progressive B cell depletion may also account for the increasing incidence of HBV reactivation as well as cytomegalovirus (11) and parvovirus B19 (12 (14, 15) . Hence, we need to clarify this controversy. As Sera et al (6) 
